Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03872024|
Recruitment Status : Not yet recruiting
First Posted : March 12, 2019
Last Update Posted : March 13, 2019
Non-Alcoholic Fatty Liver is a common clinical and histological condition associated with metabolic syndrome in patients with and without excess body weight. It represents the most common cause of liver disease in the western world and it is characterized by an excess accumulation of fatty vacuole within hepatocytes.
Patients with non-alcoholic fatty liver disease (NAFLD) can progress to non-alcoholic steatohepatitis (NASH), and then into cirrhosis and its complications.
The prevalence of hepatic steatosis goes from 16 to 31% in the general population, from 50 to 80% in the obese population and up to 96% in morbidly obese patients. As the majority of obese individuals have NAFLD, non-invasive and widely applicable screening tools for the assessment of liver fibrosis and steatosis are needed. The detection in early stages is the main predictive factor of the long-term outcome.
Liver biopsy has traditionally been the gold standard for the assessment of patients with NAFLD, although the well-known limitations. Among the non-invasive tools available in the market, the FibroScan® (Echosens™, Paris, France) has been shown to be a useful tool for diagnosing fibrosis and steatosis in patients with suspected NAFLD. The FibroScan® is an ultrasound-based vibration-controlled transient elastography (VCTE™) device dedicated to liver stiffness measurement (LSM) and the controlled attenuation parameter (CAP).
Several clinical studies have shown the benefit of measuring hepatic stiffness with the FibroScan® in overweight/moderately obese persons. The ability to identify significant fibrosis and cirrhosis has been demonstrated in normal and overweight patients affected with chronic hepatitis B and C, biliary diseases, alcohol related liver disease and NAFLD.
However, subcutaneous fat attenuates the transmission of shear waves into the liver and the ultrasonic signals used to measure their speed of propagation. When scanning morbidly obese patients (BMI≥35 kg/m²) with the XL+ probe, unreliable results occur mainly due to obesity. Therefore, the XL probe has been enabled to expand the applicability of the FibroScan® but, the realization of the XL+ examination is still very difficult in the case of morbidly obese patients. This is why to reduce this failure rate, Echosens has worked on developing the XXL probe specifically for measuring the LSM in morbidly obese patients.
|Condition or disease||Intervention/treatment||Phase|
|Obesity, Morbid Liver Fibrosis||Device: 3 XXL probe prototypes of the FibroScan 630 Research Model||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||180 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients - NEO Study|
|Estimated Study Start Date :||April 1, 2019|
|Estimated Primary Completion Date :||March 31, 2020|
|Estimated Study Completion Date :||March 31, 2020|
Experimental: Morbidly obese adult patients
Only one group of patients in the study: morbidly obese adult patients who will have an examination with the 3 XXL probe prototypes of the FibroScan 630 Research Model
Device: 3 XXL probe prototypes of the FibroScan 630 Research Model
After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:
- Liver biopsy: fibrosis stage from F0 to F4 with Kleiner (NASH CRN) scoring system [ Time Frame: 12 months ]A liver biopsy will be performed during the bariatric surgery and will be sent to a centralized pathologist that will quantify the fibrosis and classify it from F0 to F4. Where F0 indicates the absence of fibrosis and F4 indicates cirrhosis.
- Number of valid measurements per probe higher than 8 [ Time Frame: 12 months ]In order to be considered as a reliable exam, at least 8 valid measurements should be taken by the XL probe and the XXL prototype probes. Invalid measurements can appear when the probe connected to the FibroScan can't take a measurement for different reasons (distance skin to capsule very big, not good positioning of the probe….).
- Liver Stiffness Measurement (LSM) from 0 to 75 kPa assessed with the FibroScan [ Time Frame: 12 months ]The FibroScan stiffness measurement relies on the propagation of elastic waves to assess the stiffness of the liver: the faster elastic waves propagates within the liver, the stiffer the organ is. The final LSM value is the median of individual LSM values using the valid measurements and is expressed in Kilo Pascal (kPa). Values obtained for the LSM with every probe will be assessed.
- Controlled Attenuation Parameter (CAP) from 100 to 400 dB/m, assessed with the FibroScan [ Time Frame: 12 months ]The intensity of ultrasonic signals received by the probe, which decrease as a function of depth and according to the medium, is measured:the CAP is the ultrasonic attenuation rate and is expressed in decibel per meter (dB/m). Values obtained for the CAP with every probe will be assessed.
- Liver biopsy: steatosis grade from S0 to S3 with Kleiner (NASH CRN) scoring system [ Time Frame: 12 months ]Measure and classify the steatosis grade (fat in the liver) by analyzing the liver biopsy. Where S0 represents the minimal steatosis grade (<5% hépatocytes with fat) and S3 indicates a steatosis with >66% hépatocytes with fat.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03872024
|Hôpital la Pitié Salpêtrière||Not yet recruiting|
|Paris, France, 75013|
|Contact: Karine Clement, Prof 0033142177031 firstname.lastname@example.org|